Literature DB >> 2566473

Identification of two main urinary metabolites of [14C]omeprazole in humans.

L Renberg1, R Simonsson, K J Hoffmann.   

Abstract

The excretion and metabolism of [14C]omeprazole given orally as a suspension was studied in 10 healthy male subjects. An average of 79% of the dose was recovered in the urine in 96 hr, with most of the radioactivity (76% of dose) being eliminated in the first 24 hr. Pooled urine (0-2 hr) from five subjects, containing about 47% of the dose, was analyzed by reverse phase gradient elution LC with radioisotope detection. Omeprazole was completely metabolized to at least six metabolites. The two major metabolites were extensively purified by LC and their structures were determined by MS with derivatization and use of stable isotopes, 1H NMR, and comparison with synthetic references. They were formed by hydroxylation of a methyl group in the pyridine ring, followed by further oxidation of the alcohol to the corresponding carboxylic acid. Both metabolites retained the sulfoxide group of omeprazole, rendering them as unstable as the parent compound at pH less than 7. They accounted for approximately 28% (hydroxyomeprazole) and 23% (omeprazole acid) of the amount excreted in the 0-2-hr collection interval. Based on in vitro studies with the synthetic metabolites in isolated gastric glands, it is unlikely that M1 and M2 will contribute to the pharmacological effect of omeprazole in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566473

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Catatonic reaction to omeprazole and disulfiram in a patient with alcohol dependence.

Authors:  R Hajela; G M Cunningham; B M Kapur; J E Peachey; P Devenyi
Journal:  CMAJ       Date:  1990-12-01       Impact factor: 8.262

2.  Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Authors:  T Andersson; C Cederberg; C G Regårdh; I Skånberg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.

Authors:  Justin D Lutz; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

4.  Development and validation of a UPLC method for rapid and simultaneous analysis of proton pump inhibitors.

Authors:  Richard T Addo; Kenneth Davis; Ruhi Ubale; Joel S Owen; E Blake Watkins
Journal:  AAPS PharmSciTech       Date:  2014-08-27       Impact factor: 3.246

Review 5.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 6.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

7.  Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

8.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

9.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

10.  Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.

Authors:  Christopher F Butler; Caroline Peet; Amy E Mason; Michael W Voice; David Leys; Andrew W Munro
Journal:  J Biol Chem       Date:  2013-07-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.